Company background

Listed on AIM and headquartered in Belfast, Diaceutics provides the world’s leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics.

Enabled by its proprietary tech platform DXRX, the world’s first diagnostic commercialisation platform for precision medicine, the company has created the largest repository of diagnostic testing data from a global network of 2,500 laboratories including over 400m patients.

With a firm belief that every patient should have access to the right treatment at the right time, Diaceutics has accelerated and improved the journey to effective patient treatment.

The brief

With ambitious plans for significant international growth over the next few years, Peter Keeling – the CEO of Diaceutics – approached Directorbank to source a highly commercial, hands-on CFO to take control and responsibility of all financial aspects of the business.

The ideal candidate would bring an exceptional track record of supporting small listed businesses on a rapid growth trajectory, providing commercial analysis and valuable insight to drive superior shareholder value. He/she would also be very experienced in communicating with investors and the wider stakeholder audience.

The process

A thorough search process drawing on Directorbank’s candidate network, referrals and wider market mapping resulted in a strong longlist of candidates. Following vigorous assessment a shortlist of seven individuals was presented to Peter and the Diaceutics team for interview. Nick Roberts was successfully appointed to the role.


Nick is a highly experienced professional with a demonstrated history of managing and developing finance functions and governance structures within high growth AIM-listed businesses.

An aspirant CFO, most recently he held the role of Head of Group Reporting at Ergomed, a full service pharmacovigilance specialist that sits within the Diaceutics ecosystem as a provider of specialist clinical trial, drug monitoring and regulatory reporting to the pharma and bio-medical sectors. Whilst here he was instrumental in the acquisition and integration of two US companies.

Previously, Nick successfully developed the finance function and growth and reporting capabilities of Ceres Power Holdings (the entrepreneurial fuel cell and electrochemical tech development company) and navigated the business through a period of high growth including two AIM market equity fund raises.